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ORIGINAL ARTICLE

Childhood-Onset Systemic Lupus Erythematosus: A Cohort Study
Shakeel Ahmed1,2, Syed Rehan Ali1, Farida Karim3, Sidra Ishaq1, Iman Qaiser1, Kanwal Nayani1 and Ayesha Ahmed4

ABSTRACT

Objective: To determine the clinical and immunological characteristics and short-term outcome of children with systemic
lupus erythematosus (SLE).
Study Design: A descriptive cohort study.
Place and Duration of Study: Paediatric Rheumatology Clinic, The Aga Khan University Hospital, Karachi, from January
2011 to December 2015.
Methodology: Clinical and immunological profile and short-term outcome of children less than 16 years of age admitted
in the paediatric ward, with the diagnosis of SLE was studied. Demographic data, clinical presentation, laboratory findings,
immunological profile and treatment regimens of these children were evaluated.
Results: Thirty-two children, satisfying the criteria of American College of Rheumatology (ACR) for SLE, were enrolled
during the study period of five consecutive years. A female predominance was observed with 28 (87.5%) patients being
female (F:M 7:1). Mean age at symptom onset was 10.5 +2.7 years; and 8.8 +2.1 years in females and males, respectively.
The mean age at diagnosis was 11.3 +2.8 years in females and 9.4 +1.9 years in males. Prolonged fever was the most
common non-specific symptom found in 27 (84%), followed by pallor in 13 (41%) patients. Twenty-two (69%) children were
found to be anemic and 18 patients (56%) having signs of arthritis at presentation. Renal involvement was observed in
15 (47%) patients. The most common laboratory finding was anemia, found in 22 (69%) of cases. The most common
immunological markers were serum anti-neutrophil antibodies (ANA), positive in 28 (88%) patients, followed by anti
double-stranded DNA antibodies, raised in 26 (81%) of cases. Out of 32, 12 patients were lost to follow-up. Of the
remaining 20 children who were followed for four years, ten (50%) went into remission.
Conclusion: Childhood-onset SLE encompasses a wide variety of manifestations with a female preponderance. Fever,
arthralgia and pallor are the most frequent clinical manifestations among the children. Hemolytic anemia (HA) is the most
common laboratory abnormality, with ANA and anti ds-DNA antibodies positivity in the majority of padiatric patients.
Key Words: Childhood-onset. Systemic lupus erythematosus. Lupus nephritis. Immunological profile. Outcome.

INTRODUCTION

Systemic lupus erythematosus (SLE) is a multisystem,
chronic, episodic, autoimmune rheumatic disease with
complex etiology, characterised by immune complex
deposition and autoantibody production mainly antinuclear antibodies (ANA). SLE causes immuno-logically
mediated tissue damage that commonly affects the skin
and musculoskeletal systems, but can affect every organ
including kidney, central nervous system, heart, lungs.1,2
The disease is commonly described in adolescent girls
and adults, but it is believed that 20% of SLE patients
have the onset of disease in their childhood. 3 Childhoodonset SLE (cSLE) is a ubiquitous disease, which is
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characterised by diverse manifestation of the disease.
There is varying epidemiologic information regarding
SLE among countries in Asia. Prevalence rate usually
falls within 30-50/100,000 population. India, Japan,
Saudi Arabia showed a lower prevalence of 3.219.3/100,000. Incidence rate as reported from various
studies, varies from 0.9 to 3.1/100,000 per annum.4

Previous studies have suggested that age at disease
onset and age at diagnosis may influence disease
expression in terms of initial clinical diagnosis, pattern of
organ involvement, and serologic findings.5 Moreover,
during recent years a more widespread awareness of
cSLE, as well as the development of newer diagnostic
techniques, has led to the recognition that the course
and overall prognosis of cSLE is less grave than
previously thought.6 In addition, studies that compared
cSLE with adult-onset SLE (aSLE) demonstrated higher
disease activity and severity in the former group.7
Childhood-onset SLE is a more severe disease due to
the higher incidence of nephritis and needs more
aggressive treatment with immunosuppressive agents.8
The studies pertaining to childhood-onset SLE in Pakistan
are limited. This study was undertaken to determine the
common clinical presentations, immunological traits and
short-term outcome in the children who have received
the standard care.
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METHODOLOGY

This cohort descriptive study was carried out on children
under the age of 16 years, presenting to the pediatric
rheumatology section, The Aga Khan University
Hospital, Karachi, from January 2011 to December
2015, who were diagnosed as SLE. Detailed history
from patients and their parents/guardians was taken. A
complete clinical examination, including musculoskeletal
examination was performed by the treating physician.
For the purpose of this study, childhood-onset SLE was
defined by the presence of any 4 of 11 criteria of the
American College of Rheumatology (ACR) used to
diagnose SLE in children aged 16 or less (Table I).9
Children with other possible, more similar, diagnoses
such as undifferentiated connective tissue disorder
with 3 or few ACR criteria, isolated cutaneous lupus
erythematosus, neonatal lupus erythematosus, druginduced lupus, and other autoimmune diseases were
excluded.

A retrospective review of files was done and information
was collected via a structured proforma prepared for the
study. Data pertaining to gender, age at onset of
symptoms and age at diagnosis, systems and organ
involvement were collected. Laboratory parameters
including hematological findings, e.g. hemoglobin,
leucocytes, platelets, inflammatory markers, erythrocyte
sedimentation rate (ESR) and C-reactive protein (CRP),
presence or absence of immunological indicators like
anti-nuclear antibody (ANA), extractable nuclear antigen
(ENA), double stranded DNA (ds-DNA) were collected.
Pathological findings, including the renal biopsy results
in children with lupus nephritis were also noted. In
addition, different therapeutic regimen offered to these
children and their short-term response was also
observed.
Data were entered, validated and analysed using
Statistical Package for Social Sciences (SPSS) version
19.0. Mean and standard deviation were expressed for
numerical variables, while frequencies and percentages
were expressed for categorical variables. As per Ethical
Review Committee (ERC) guidelines, the study protocol
was granted exemption (1935-Ped-ERC-11).
The Chi-square test was applied with the p-value of
<0.005 being taken as statistically significant.

RESULTS

A total of 32 patients were enrolled during the study
period of five consecutive years. A female predominance
was observed, 28 (87.5%) of the patients being females
(F:M 7:1). Mean age of onset of symptoms varied among
males and females.

Mean age at symptom onset was 10.5 +2.7 years, and
8.8 +2.1 years in females and males, respectively. The
mean age at diagnosis was 11.3 +2.8 years in females
and 9.4 +1.9 years in males. Consanguinity was present
among 15 47% of the parents of the patients.
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Prolonged fever was the most common non-specific
presenting symptom in a majority of the children.
Prolonged fever presented in 27 (84%) children followed
by pallor in 13 (41%), and anorexia and fatigue in 10
(31%) each. Other symptoms included alopecia (n=10,
31%), weight loss (n=9, 28%) and myalgia (n=8, 25%).

The most common specific clinical manifestation in these
children, based on the ACR criteria for the diagnosis of
SLE, was anemia, which was present in 22 (69%)
patients. Arthritis is the second common manifestation
after anemia; 18 (56%) patients have polyarthritis at
presentation, large joints mainly knee, ankle, wrist and
elbow joints are involved in most of the patients. Malar
rash was found in eight (25%) patients while
photosensitivity and discoid rash were seen in 3 (9%).
Ten (31%) patients had muco-cutaneous ulcers at
presentation. Renal involvement was observed in
15 (47%) patients who presented with hematuria,
proteinuria, edema and hypertension. Nine of them, who
had heavy proteinuria, underwent renal biopsy. Five
(16%) patients exhibited neuropsychiatric symptoms; out
of which, two had new onset seizures, two had
psychosis; while one already had seizure disorder
whose symptoms were exacerbated with the onset of
the disease. Pericardial effusion was found in four
(12.5%) patients, out of which one required pericardiocentesis due to cardiac de-compensation.
Various laboratory parameters in patients with SLE are
shown in Table II. Anemia (hemoglobin <10 g/dl) was the
most frequent hematological abnormality observed in
22 patients (69%); out of which 13 (41%) patients were
severely anemic (Hb <6 gm/dl) and required urgent
transfusion of packed RBC's. Direct coombs was
positive in 18 (56%) who had evidence of hemolysis with
raised reticulocyte count. The remaining had microcytic
hypochromic anemia. Leucopenia (white cell counts
<4,000/mm3) was seen in 7 (22%) patients; 12 (37%)
had thrombocytopenia (platelet count <150,000/mm3) at
admission. It was observed that acute phase reactants,
including ESR and CRP, were also raised in most of the
patients with the frequency of 25 (78%) and 22 (69%),
respectively. Low serum complements C3 & C4 were
observed in 25 (78%) and 11 (34%) patients, respectively.
Immunological markers demonstrated that overall
28 (88%) patients had ANA positivity, followed by anti
ds-DNA in 26 (81%) children; anti smith antibody was
elevated in 11 (34%) children. Laboratory and immunological profile is summarised in Table II.
Out of 15 patients who presented with renal manifestations,
nine underwent renal biopsy. A majority of them (six),
were of WHO class IV, while three were of class I, III and
V each. Class III was treated with azathioprine, and
class V with cyclosporine. Patients with class IV
received monthly cyclophosphamide infusion for a
period of seven months followed by quarterly infusion for
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Table I: ACR criteria for diagnosing SLE.
ACR criteria
Malar rash

Discoid rash

Serositis; pleuritis, pericarditis
Oral ulcers

Arthritis; non-erosive
Photosensitivity

Neurological disorders; seizure, psychosis

Blood disorders; hemolytic anemia, leucopenia, lymphopenia,
Renal disease; proteinuria, RBC casts
Positive antinuclear antibodies

Immunological abnormalities (positive anti ds-DNA, anti-Sm, etc.)

Table II: Laboratory and immunological profile of children with c-SLE.
Laboratory results

Number (%)

Leokopenia (<4,000/mm3)

7 (22)

Anti-SM

Figure 1: Follow-up results of the studied cohort of children with SLE.

11 (34)

Serum complement C3

two and half years. Mycophenolate mofetal was used in
patients who refused the cyclophosphamide infusion.

11 (34)

Thrombocytopenia (<150,00/ mm3)

12 (37)

Coombs (positive)

18 (56)

Elevated CRP

22 (69)

Anemia (HB <10g/dl)

22 (69)

Serum complement C3

25 (78)

Anti DS-DNA

26 (81)

ESR (>20 mm/hr)

25 (78)

ANA

28 (88)

Table III: Comparative analysis of our study and two multicenter studies.
Variables

Demographic data
Gender

Female
Male

The present
study
(n=32)
Percent

Brazilian
French
multicenter study18 multicenter study19
(n=847)
(n=155)
Percent *¥
Percent Ý

87.5

12.5

Mean age of diagnosis (years) 10.35

Non-specific symptoms
Fever

84

84

16

9.35

11.5

Weight loss

28

27

62

60

Arthritis

56

68

62

Discoid rash

9

7

6.5

32

10.5

51

58

27

Clinical manifestations, based on ACR criteria
Malar rash

Photosensitivity

25

54

9

42

12.5

30

Neurological symptoms

16

28

Hemolytic anemia

69

20

Oral ulcers
Serositis

Renal disorders

Laboratory findings
Leukopenia

Thrombocytopenia

Immunological profiles

31

47

22
37

ANA

88

Anti-Sm

34

Anti ds-DNA

81

23

14
99

67

38

-

39

13
-

20

35

28

97

93

32

* Mean of the percentages in the three age groups ranging from <2 years till <18 years.
¥ Represented white (patients with white European ancestors), African-Latin Americans
(patients born in Latin America with at least 1 African ancestor), Asian (patients with Asian
ancestors), and other/unknown.
Ý Represented white, black, or North African children, but was significantly higher number of
Asian children.

Several anti-inflammatory and immunosuppressant
drugs were given to these children. Majority (91%) were
treated with hydroxychloroquine. The other commonly
prescribed drugs were steroids and NSAIDS given in
88% and 75% children, respectively. Immunosuppressive
like cyclophosphamide, azathioprine and mycophenolate
mofetal were used in children with lupus nephritis and
with neurological manifestations. Other therapeutic
measures included blood transfusion in 41% and
anticonvulsant medication in 9% of the children.
Out of 32 patients, 20 (62.5%) were followed for 4 years
(Figure 1). Twelve patients (37.5%) were lost to followup due to certain reasons, the major one being due to
lack of accessibility as they were from the remote areas.
Other reasons included prolonged nature of therapy and
financial constraints.

During the follow-up period, out of 20 patients, 10 (50%)
patients showed a good response to therapy and were in
clinical and biochemical remissions. Five (25%) children,
who had lupus nephritis, had active disease and were on
treatment. Five (25%) children died during the therapy;
two of them due to disseminated tuberculosis, one
because of chronic renal insufficiency and two died
because of severe sepsis.

DISCUSSION

There is compelling evidence that the presentation of
childhood SLE (cSLE) is not only diversified in terms of
disease manifestations, but it tends to be more serious,
with renal involvement, and is associated with a more
aggressive clinical course and an increased need for
heavy immunosuppressive therapy.2,10-12

In this descriptive observational study, the authors found
that the prevalence of cSLE is quite high in the female
population, with a female to male ratio of 7:1, which is
nearly similar to most previous reports on cSLE.5,7,13,14
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Males present early as compared to females; mean
age at onset of disease in males was 8.8 +2.1 years
compared to females whose mean age was 10.5 +2.7
years. In addition, we observed that fever and pallor
were the most common non-specific manifestations.
Furthermore, we also observed the high frequency of
renal manifestations in our population. Most of the
previous studies have underlined the frequent and
debilitating involvement of renal pathology in cSLE.6,8,15-17
Coomb's positive hemolytic anemia was the most
common laboratory derangement; whereas, ANA
positivity followed by anti ds-DNA elevation were the
most frequent immunologic findings.

A comparative analysis of two multicenter studies on
clinical features, organ involvement, laboratory and
immunologic profile of c-SLE patients showed
comparable results with minor contrasts with this study
as shown in Table III.18,19
In addition to the age at onset of the disease, inter-ethnic
differences have also influenced the disease course in
the pediatric population. Mortality is higher in certain
racial and ethnic groups,20 including poorer prognosis in
African-American and Hispanic patients. Severe nephropathy is significantly more frequent in Asian patients.21

Arthritis and fever were the two most common manifestations, in all ethnicities including American, African,
European and Asian; as evidenced in other multicenter
studies.22 However, this study results had significant
differences in frequencies of other manifestations as
compared to these multicenter cohorts in different races.
Malar rash has occurred in around 58 to 60% of
American and European children and is the one of the
most common manifestations at the time of presentation.23
Similarly, hemolytic anemia (HA) was found to be the
most common laboratory abnormality in up to 69% (22
children), which is quite close to occurrence of HA as
part of cSLE in African children in 82%, compared to only
20% and 27% children of American and European
descent.5,21

Although the racial difference had presented with
substantial variation in symptomatology and laboratory
findings, immunological profiling did not reveal such
remarkable disparities. ANA is positive in up to 88% of
patients in this study and analogous results have been
demonstrated in children of all other races and range
from 92-99%.4,5,21 Anti ds-DNA antibodies did not show
comparable results among different ethnicities with
positivity in 81% in this study; whereas, it was found
positive in up to 67% and 85-95% in American and
European ancestry.21
A comparison of cSLE between this study and an Indian
series showed analogous findings representing disease
progression in Asian population.24
Limitations of the study include small sample size and
single center study.
368

Strength of the study is that it is among the few reported
studies from the region and can be used as a parent
study to explore the disease further. In addition, owing to
the rarity of SLE overall and especially in the pediatric
population, we did not come across any comparative
work done on cSLE in Pakistan.

CONCLUSION

Childhood-onset SLE encompasses a wide variety of
manifestations with a greater female preponderance. It
is associated with an aggressive disease course as
compared to adult SLE. Biopsy proven lupus nephritis is
the most common complication reported. Hemolytic
anemia is the most common laboratory derangement
and ANA and anti ds-DNA are positive in the majority of
c-SLE patients. A detailed history, thorough review of
systems, complete physical examination, complete
blood count, urinalysis, and a high index of suspicion
help make the correct diagnosis of SLE in patients. Early
diagnosis and early treatment can improve the
prognosis of children with SLE.
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